Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Treatments

Topic: Risk, prevention and care in population studies

This initial report describes the ongoing 4-year longitudinal study and provides baseline results, which confirm the feasibility of obtaining home-based clinical information via mail or telephone. Initial results for the experimental instruments and for the book club are reported in separate accompanying articles.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Ferris, S. H., Aisen, P. S., Cummings, J., Galasko, D., Salmon, D. P., Schneider, L., et al. (2006). ADCS Prevention Instrument Project: overview and initial results. Alzheimer disease and associated disorders. https://doi.org/10.1097/01.wad.0000213870.40300.21

Vancouver

Ferris SH, Aisen PS, Cummings J, Galasko D, Salmon DP, Schneider L, et al. ADCS Prevention Instrument Project: overview and initial results. Alzheimer disease and associated disorders. 2006. doi:10.1097/01.wad.0000213870.40300.21. PMID: 17135805.

BibTeX

@article{ferris2006-17135805,
  author  = {Ferris, S. H. and Aisen, P. S. and Cummings, J. and Galasko, D. and Salmon, D. P. and Schneider, L. and Sano, M. and Whitehouse, P. J. and others},
  title   = {{ADCS Prevention Instrument Project: overview and initial results}},
  journal = {Alzheimer disease and associated disorders},
  year    = {2006},
  doi     = {10.1097/01.wad.0000213870.40300.21},
  pmid    = {17135805},
  url     = {https://doi.org/10.1097/01.wad.0000213870.40300.21}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This report sets out the ADCS Prevention Instrument Project, a 4-year longitudinal study. Its baseline results "confirm the feasibility of obtaining home-based clinical information via mail or telephone", which means prevention research could gather some data without clinic visits. It tests no treatment and shows nothing about preventing Alzheimer's. Results for the experimental instruments and the book club are in separate companion articles.

Study details

How this study scored 61/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 11 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 1 of 2; Times cited 4 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 2 of 6; Still being cited 1 of 4; Senior author's track record left out, no data; Institution's track record 2 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 59 of the 96 points it could be judged on, which is 61 of 100. Total 61 of 100.59 of the 96 points we could judge = 61 of 100

Published in a peer-reviewed journal, and it is a randomised controlled trial. Scored zero for effect reported because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 59 of the 96 points we could judge it on, which is 61 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer disease and associated disorders)
Journal's citation record 1 / 4 Alzheimer Disease & Associated Disorders: journal h-index 131 (OpenAlex, 2026-10-29)
Study design 11 / 12 A randomised controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2006 — older than 20 years, still counted
Sample size 2 / 4 644 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 1 / 2 Randomised (as stated in the record)
Times cited 4 / 7 Cited 75 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 3.4 citations a year over 22 year(s) since 2006
Impact for its field and year 3 / 6 Cited 3.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 6 other studies in this library
Still being cited 1 / 4 Cited 10 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author and Leon J. Thal holds only 1 work(s), too few to judge a track record — left out of this score
Institution's track record 2 / 3 University of California, Los Angeles: institution h-index 1,923 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 8 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 17135805)
Free to read 0 / 2 Behind a paywall — scores zero
Points 59 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 59 of the 96 points we could judge it on is 61 out of 100.
Total 61 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

6 studies in the alzhub library list this one in their references.

Related studies in Treatments

Also in Treatments

166 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.

Similar studies

More on Treatments

See all studies in Treatments →